Type to search

Diseases News Oncology

Immunovia Further Strengthens IP Portfolio for its IMMray ™ PanCan-d Signature

Immunovia Further Strengthens IP Portfolio for its IMMray ™ PanCan-d Signature | Pharmtech Focus

Immunovia AB (publ) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent application for the IMMray ™ PanCan-d test available exclusively from Immunovia, Inc. This means that the Immunovia IMMray ™ PanCan-d test signature will be further covered by the resultant patent once it is issued.

Immunovia’s IMMray ™ PanCan-d is the first ever blood test dedicated to the early detection of pancreatic cancer. Detection of the disease at an early stage, while still resectable, has the potential to increase survival rates for pancreatic cancer patients. The test is available for individuals in the familial and hereditary high-risk group in the United States, since August 2021.

“We are pleased that the USPTO has decided to allow Immunovia this patent, which will further secure the intellectual property for Immunovia’s commercial test in the US. The patent further strengthens our extensive IP portfolio consisting of seven patent families covering biomarkers in pancreatic cancer. With multiple granted patents and multiple patent applications in different geographies, we have a broad protection of our innovations”, says Philipp Mathieu, Acting CEO and President, Immunovia AB.

The patent application, no. 17/377,473, for which the Notice of Allowance has issued, was submitted to USPTO’s prioritized patent examination program, Track One. 


You Might also Like

Related Stories

Next Up